1. Introduction {#sec1-antibiotics-09-00307}
===============

Rifampin (RF) was introduced as a part of the combinational chemotherapy regimen for tuberculosis (TB) during the 1960s. This has revolutionized TB treatment by reducing the duration of antitubercular therapy (ATT) and improving the cure rates \[[@B1-antibiotics-09-00307],[@B2-antibiotics-09-00307]\]. The antimicrobial effect of RF on *Mycobacterium tuberculosis* and the development of RF resistance is concentration-dependent \[[@B3-antibiotics-09-00307],[@B4-antibiotics-09-00307]\]. RF exhibits antimycobacterial action by arresting the DNA-directed RNA synthesis of *Mycobacterium tuberculosis* through interaction with the β subunit of RNA polymerase (RNAP) \[[@B5-antibiotics-09-00307],[@B6-antibiotics-09-00307]\]. The primary mechanism of RF resistance is due to the mutations in the *rpoB* gene that encode for the β-subunit of RNA polymerase. The most common mutations in the *rpoB* gene are found in the *rpoB* 531, *rpoB* 526 and *rpoB* 516 codons of the RF resistance determining region (RRDR) \[[@B7-antibiotics-09-00307],[@B8-antibiotics-09-00307]\]. Recent evidence has shown that higher doses of RF from the currently recommended dosage regimens resulted in better treatment outcomes in TB patients \[[@B9-antibiotics-09-00307],[@B10-antibiotics-09-00307]\]. A recent comprehensive meta-analysis reported a wide range of interstudy heterogeneity in RF pharmacokinetic parameter estimates. Many variables such as HIV, TB and diabetes status, drug combinations, duration of therapy and dosing frequency could not explain the heterogeneity in the pharmacokinetics of RF. An increase in RF dose from the common weight-based dosing category of 8--12 mg/kg to at least 25 mg/kg was required to achieve plasma pharmacokinetic-pharmacodynamic (PK/PD) targets \[[@B11-antibiotics-09-00307]\]. Single nucleotide polymorphisms (SNPs) represent the most common type of genetic polymorphism in humans \[[@B12-antibiotics-09-00307]\]. Multiple studies have reported the association of various genetic polymorphisms with significant variances in plasma RF levels in TB patients. This provides us with an exciting opportunity to review for assessing the potential impact of SNPs as an important driver for plasma RF exposure variability in TB patients.

RF is metabolized in the liver into an active metabolite 25-desacetylrifampin and excreted almost equally via biliary and renal routes \[[@B13-antibiotics-09-00307]\]. B-esterase and Arylacetamide deacetylase (AADAC) enzymes have been reported to catalyze the deacetylation of RF to 25-deacetylrifampin \[[@B14-antibiotics-09-00307],[@B15-antibiotics-09-00307]\]. Membrane drug transporters are recognized to be important determinants of absorption, distribution, metabolism and excretion (ADME) of drugs and consequently influence their pharmacokinetic (PK), therapeutic efficacy and safety profiles. Solute carrier (SLC) transporters and the adenosine triphosphate (ATP)-binding cassette (ABC) transporters represent two superfamilies of membrane drug transporters. They are primarily involved in the in and out transport of drugs across tissues and cells in the human body. The SLC and ABC superfamily account for about 400 membrane transporters, out of which around 32 are clinically relevant \[[@B16-antibiotics-09-00307],[@B17-antibiotics-09-00307]\]. Pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are nuclear hormone receptors that are involved in the transcriptional regulation of various drug-metabolizing enzymes and transporters \[[@B18-antibiotics-09-00307]\]. Multiple studies have revealed the potential role of PXR and CAR in the transcriptional regulation of SLC and ABC proteins \[[@B19-antibiotics-09-00307],[@B20-antibiotics-09-00307],[@B21-antibiotics-09-00307]\]. RF disposition is influenced by sinusoidal influx transporter SLCO1B1 and efflux transporter ABCB1 during hepatic uptake and biliary excretion, respectively \[[@B22-antibiotics-09-00307],[@B23-antibiotics-09-00307],[@B24-antibiotics-09-00307]\].

Vitamin D regulates gene transcription by binding to Vitamin D Receptor (VDR). The 427 amino acid VDR is encoded by the *VDR* gene \[[@B25-antibiotics-09-00307]\]. Vitamin D is involved in the modulation of innate and adaptive immune responses through the mediation of multiple genes. These genes regulated by the transcription factor VDR encode for proteins that relate to acute response to infection, general functions in infection and for autoimmune responses \[[@B26-antibiotics-09-00307]\]. The degree of immune responses elicited is associated with the circulating levels of Vitamin D \[[@B27-antibiotics-09-00307]\]. Vitamin D deficiency (VDD) and *VDR* gene polymorphisms are associated with an increased risk for the development of TB \[[@B28-antibiotics-09-00307]\]. VDR has been reported to induce the expression of *SLCO1B1* \[[@B29-antibiotics-09-00307]\]. Furthermore, RF can also result in the reduction of Vitamin D levels by increasing its clearance through the agonist and inducing action on PXR and CYP3A4, respectively \[[@B30-antibiotics-09-00307],[@B31-antibiotics-09-00307]\]. Hence, the genetic polymorphisms of these metabolizing enzymes, drug transporters and/or their transcriptional regulators and *VDR* gene and its pathway regulators may influence the RF pharmacokinetics.

Relevant studies were searched in databases like PubMed, MEDLINE, EMBASE, Web of Science and Google Scholar. The following Medical Subject Headings (MeSH) words were used as part of our search strategy: antitubercular agents, antitubercular drugs, rifampin, rifampicin, genetic polymorphism, genetic susceptibility, pharmacogenetics, pharmacogenomics, genetic association study, genetic association analysis, tuberculosis, single nucleotide polymorphisms, pharmacokinetics, population pharmacokinetics, *SLCO1B1*, *ABCB1*, *PXR, CAR*, carboxylesterase 1 (*CES1*), carboxylesterase 2 (*CES2*), *AADAC* and *VDR*. The scope of the review is limited to studies that recruited TB patients, regardless of age and HIV status who were either already established on ATT or commencing treatment. Association between at least one genetic variant and RF pharmacokinetic outcome was assessed ([Figure 1](#antibiotics-09-00307-f001){ref-type="fig"}). Studies without any formal evaluation of genotype effects for RF exposures were excluded. From the reference lists of the articles, we extracted additional literature relevant to the topic. Only publications in the English language were considered for this review.

2. SLCO1B1 {#sec2-antibiotics-09-00307}
==========

The organic anion transporting polypeptide 1B1 (OATP1B1) is a 691 amino acid protein expressed predominantly on the basolateral (sinusoidal) membrane of hepatocytes. It is encoded by the solute carrier organic anion transporter family member 1B1 (*SLCO1B1)* gene (spans 15 exons) located on chromosome 12. OATP1B1 is one of the major membrane influx transporters that regulate the active hepatic uptake of substrates from the bloodstream into the hepatocyte \[[@B16-antibiotics-09-00307],[@B32-antibiotics-09-00307]\]. RF is a strong substrate of the OATP1B1 transporter protein \[[@B33-antibiotics-09-00307],[@B34-antibiotics-09-00307]\]. Around 190 genomic variants with minor allele frequency higher than 5% were identified with the *SLCO1B1* gene. Among these variants, rs4149056 and rs2306283 have been commonly identified and well-characterized \[[@B35-antibiotics-09-00307]\].

The missense SNP rs4149056 located in exon 5 (also known as c.521T\>C; with T allele defined as the wild-type allele and the C allele as a variant) causes a change of amino acid from valine to alanine at residue 174. This variant is reported to have reduced expression and activity of *SLCO1B1* in vitro and in vivo. Hence, drugs that are substrates for OATP1B1 with c.521T\>C may tend to have elevated plasma concentrations due to reduced uptake/transporter activity \[[@B36-antibiotics-09-00307],[@B37-antibiotics-09-00307]\]. Allegra et al. have reported higher plasma RF concentrations in TB patients with *SLCO1B1* rs4149056 polymorphism. Multivariate linear regression analysis revealed that *SLCO1B1* rs4149056 genotype was found to be a positive predictive factor for increased plasma RF trough concentration (C~trough~, *p* = 0.048, β = 0.345, 95% CI \[6.458--1313.556\]) and maximum concentration (C~max~, *p* = 0.019, β = 0.432, 95% CI \[452.896--4571.730\] at second week of ATT \[[@B38-antibiotics-09-00307]\]. The frequency of *SLCO1B1* rs4149056 genotype was reported to be 28.3%, 5.7%, 14.9% and 14.8% in Amerindian, African descent, Mulatto and Caucasian descent ethnic groups, respectively \[[@B39-antibiotics-09-00307]\]. Mwinyi et al. reported a frequency of 15% and 12.2% in German and Turkish populations, respectively, whereas 15% prevalence was reported among the UK population for *SLCO1B1* rs4149056 genotype \[[@B40-antibiotics-09-00307],[@B41-antibiotics-09-00307]\].

rs2306283 (c.388A\>G) is a missense SNP located in the exon 4 of the *SLCO1B1* gene that causes a change of amino acid from asparagine to aspartic acid at amino acid position 130. The functional consequences of this variant reported by different in vitro and in vivo studies have yielded conflicting results and may be substrate-specific \[[@B36-antibiotics-09-00307],[@B42-antibiotics-09-00307]\]. Dompreh et al. had reported that the *SLCO1B1* rs2306283 polymorphism was associated with lower RF concentration in the pediatric TB population. Two patients (1.8%) with the *SLCO1B1* \*1b homozygous variant (AA genotype) had significantly lower RF C~max~ (1.81 (0.81--2.80) μg/mL) and area under the time-concentration curve from 0 to 8 h (9.33 (2.35--16.31) μg\*h/mL) and higher apparent oral clearance (44.54 (15.38--73.69) L/h) and apparent volume of distribution (109.23 (54.86--163.59) L) than did those with the wild type (GG genotype) in a pairwise analysis \[[@B43-antibiotics-09-00307]\]. However, other studies have reported higher frequencies of the *SLCO1B1* \*1b homozygous variant (AA genotype) in Chilean (18.6%), Macedonian (33.1%) and Albanian (30.8%) population \[[@B44-antibiotics-09-00307],[@B45-antibiotics-09-00307]\].

Chigutsa et al. and Gengiah et al. reported a high prevalence of *SLCO1B1* rs4149032 (g.38664C\>T), which is an intron 2 haplotype tagging SNP (tSNP). *SLCO1B1* rs4149032 polymorphism was found to be associated with lower RF exposures in the African population suggesting the need for increasing the RF dose \[[@B46-antibiotics-09-00307],[@B47-antibiotics-09-00307]\]. The functional consequences of *SLCO1B1* rs4149032 on gene expression and on transporter activity are not yet known. Chigutsa et al. reported an allele frequency of 70% for the *SLCO1B1* rs4149032 polymorphism in the South African pulmonary TB (PTB) patients. Patients who were heterozygous and homozygous for the rs4149032 polymorphism in this population had reductions in RF bioavailability by 18% and 28%, respectively. Simulations showed that *SLCO1B1* rs41490932 carriers had a predicted reduction in C~max~ of \< 8 mg/L and an increase in the daily rifampin dose by 150 mg in the PTB patients in these population would help in achieving plasma concentrations similar to those of wild-type individuals \[[@B46-antibiotics-09-00307]\]. Gengiah et al. reported an allele frequency of 76% for the *SLCO1B1* rs4149032 polymorphism in the TB-HIV coinfected patients in South Africa. The median (IQR) RF concentrations at 2.5 h postdose were 3.4 (2.7--4.7) μg/mL, 3.7 (2.8--5.0) μg/mL and 5.3 (3.8--6.7) μg/mL for homozygous variant, heterozygous variant and wild type carriers of *SLCO1B1* rs4149032 polymorphism, respectively, which was well below the recommended target range of 8 to 24 μg/mL \[[@B47-antibiotics-09-00307]\]. Mukonzo et al. reported an allelic frequency of 66% for the *SLCO1B1* rs4149032 polymorphism in the Ugandan population \[[@B48-antibiotics-09-00307]\].

Lower RF exposures were reported with *SLCO1B1* rs11045819 polymorphism in a study conducted by Weiner et al. \[[@B49-antibiotics-09-00307]\]. *SLCO1B1* rs11045819 (c.463 C\>A) polymorphism is a missense variant, present on the exon 4 of the *SLCO1B1* that cause a change of amino acid from proline to threonine at amino acid position 155 \[[@B49-antibiotics-09-00307]\]. *SLCO1B1* rs11045819 polymorphism was found to reduce the systemic exposure of the substrate for OATP1B1 transporter \[[@B50-antibiotics-09-00307]\]. Weiner et al. reported the prevalence of *SLCO1B1* rs11045819 polymorphism as 19% (*n* = 7) in African TB patients, 11% (*n* = 4) in TB patients of US and Spain and 25% (*n* = 4) among the healthy US population (controls). Patients with the *SLCO1B1* rs11045819 variant allele (CA) had 42% lower RF exposure (25.6 μg\*h/mL), 34% lower peak concentration levels (5 μg/mL) and 63% greater apparent oral clearance (22 L/h) compared to the wild type allele (CC) \[[@B49-antibiotics-09-00307]\].

However, recent studies from the African population have not found any association with *SLCO1B1* polymorphisms and RF exposures among TB patients \[[@B48-antibiotics-09-00307],[@B51-antibiotics-09-00307],[@B52-antibiotics-09-00307]\]. Similarly, studies conducted by Ramesh et al. and Jeremiah et al. in the Indian and Tanzanian population, respectively, did not report any association of *SLCO1B1* polymorphisms with plasma RF exposures ([Table 1](#antibiotics-09-00307-t001){ref-type="table"}) \[[@B53-antibiotics-09-00307],[@B54-antibiotics-09-00307]\]. The association of *SLCO1B1* rs4149056, rs2306283, rs4149032 and rs11045819 polymorphisms with RF pharmacokinetics reported in certain studies were not replicated in other studies that can be attributed due to multiple factors such as lower sample population, ethnic variations, variations in the criteria and timings of sample collection, analytical variations and interindividual factors such as variations in body weight and medication adherence. Therefore, additional studies are warranted to characterize the functional consequences of *SLCO1B1* rs4149056, rs2306283, rs4149032 and rs11045819 polymorphism on RF pharmacokinetics in other ethnic groups.

3. ABCB1 {#sec3-antibiotics-09-00307}
========

*ABCB1* (or *MDR1*) gene is located on chromosome 7 and consists of 29 exons in a genomic region spanning 251.3 kb. It is one of many ABC genes that encode for the 1280 amino acid ABCB1 transporter protein (P-glycoprotein). P-glycoprotein (Pgp) is a multidomain integral membrane protein that utilizes the energy generated from the ATP hydrolysis to translocate solutes or ions from intracellular to extracellular membranes (efflux pump) in eukaryotes \[[@B56-antibiotics-09-00307],[@B57-antibiotics-09-00307],[@B58-antibiotics-09-00307]\]. RF is a substrate of the Pgp efflux pump \[[@B59-antibiotics-09-00307]\]. rs1128503, rs2032582 and rs1045642 are the most commonly found SNPs in the *ABCB1* gene \[[@B60-antibiotics-09-00307]\]. rs1128503 and rs1045642 are synonymous mutations, whereas rs2032582 is a missense mutation \[[@B61-antibiotics-09-00307]\]. None of the studies were able to infer any association between *ABCB1* polymorphisms and RF pharmacokinetics ([Table 2](#antibiotics-09-00307-t002){ref-type="table"}). These studies have explored the association of only a limited number of *ABCB1* polymorphisms with the RF exposures. There are about 8643 single nucleotide variants (SNV) reported for the *ABCB1* gene. The functional consequences of rare *ABCB1* variants that may have a significant effect on drug pharmacokinetics have not been largely elucidated \[[@B58-antibiotics-09-00307]\]. Hence, additional studies with other genetic variants are required to establish the impact of *ABCB1* polymorphisms with the RF exposure.

4. PXR and CAR {#sec4-antibiotics-09-00307}
==============

PXR and the CAR are members of the group I of the subfamily 1 of nuclear receptors (NRs) that are involved in regulating the transcription of a wide range of drug-metabolizing enzymes and drug transporters genes \[[@B62-antibiotics-09-00307],[@B63-antibiotics-09-00307]\]. RF is a substrate for SLCO1B1 and ABCB1 protein and the transcription of genes encoding these proteins are regulated by the *PXR* and *CAR*. Few studies have explored the possibility of association of the SNPs of these genes with the plasma RF levels. The *PXR* (or *NR1I2*) gene located on chromosome 3 and consisting of 9 exons encodes for the PXR \[[@B64-antibiotics-09-00307]\]. rs2472677 and rs1523130 variants are present in the intron 1 and 5′UTR regions of the *PXR* gene, respectively. These regions represent the transcription factor binding sites of *PXR* regulatory regions \[[@B65-antibiotics-09-00307],[@B66-antibiotics-09-00307]\]. The *CAR* (or *NR1I3*) gene located on chromosome 1 and consisting of 9 exons encodes for the CAR \[[@B67-antibiotics-09-00307],[@B68-antibiotics-09-00307]\]. The rs2307424 variant is due to a synonymous substitution (c.540 C\>T) in the *CAR* gene \[[@B69-antibiotics-09-00307]\]. None of these SNPs in *PXR* and *CAR* affected RF exposures ([Table 3](#antibiotics-09-00307-t003){ref-type="table"} and [Table 4](#antibiotics-09-00307-t004){ref-type="table"}).

5. CES1 and CES2 {#sec5-antibiotics-09-00307}
================

RF is primarily metabolized to 25-desacetylrifampin by B-esterase \[[@B70-antibiotics-09-00307]\]. B-esterases family comprises CES, acetylcholinesterase and butyrylcholinesterase enzymes \[[@B14-antibiotics-09-00307]\]. Among these enzymes, CES exhibits broad substrate specificity and is involved in the metabolism of a wide range of endobiotic and xenobiotic compounds by hydrolyzing ester, thioester, amide and carbamate linkages. Human CES1 and human CES2 encoded by *CES1* and *CES2* gene, respectively, represent the two major isoenzymes of CES that are expressed in the liver \[[@B71-antibiotics-09-00307]\]. Over the past decade, several *CES1* and *CES2* functional genetic variants associated with significant variations to various drug therapy responses have been reported. Hence, assessing the genetic polymorphisms of these genes with the pharmacokinetics of the substrate drugs becomes relevant \[[@B72-antibiotics-09-00307]\]. The *CES1* and *CES2* genes are located on chromosome 16 and consist of 14 and 12 exons, respectively \[[@B73-antibiotics-09-00307]\].

Sloan et al. reported that the rs12149368 variant present on the exon 1 (5'UTR) region of the *CES1* gene does not affect the plasma RF concentration ([Table 5](#antibiotics-09-00307-t005){ref-type="table"}) \[[@B55-antibiotics-09-00307]\]. Song et al. evaluated 10 SNPs: c.-2548C\>T and c.-2263A\>G variants in the promoter region, c.269-965A\>G, c.474-152T\>C, c.615 + 120G\>A, c.1612 + 136G\>A and c.1613-87G\>A variants of the intron regions and c.1872\*69A\>G, c.1872\*302_304delGAA, c.1872\*445C\>T variants of the 3′UTR regions of the *CES2* gene with the RF levels. Increased plasma RF concentrations in TB patients were associated with the *CES2* c.-22263A\>G (g.738A\>G) variant. The allelic frequencies for this variant were reported to be 0.33 in TB patients and 0.31 in controls and plasma RF concentrations were 8.9 ± 2.9 mg/L, 10.5 ± 3.1 mg/L and 13.9 ± 7.4 mg/L in homozygotes carrying major allele, heterozygotes and homozygotes carrying minor allele, respectively. Results of luciferase reporter analysis revealed that the change from A to G in *CES2* c.-22263A\>G variant was associated with a consistent decrease in luciferase activity, which may result in decreased RF metabolism and increased plasma RF concentration \[[@B74-antibiotics-09-00307]\]. However, Dompreh et al. did not find any changes in the RF exposures with the *CES2* rs3759994 variant ([Table 5](#antibiotics-09-00307-t005){ref-type="table"}) \[[@B43-antibiotics-09-00307]\].

6. AADAC {#sec6-antibiotics-09-00307}
========

AADAC is an enzyme expressed primarily in the human liver and intestine that causes the hydrolysis of many drugs \[[@B75-antibiotics-09-00307]\]. Nakajima et al. reported that human AADAC was the enzyme responsible for the deacetylation of RF to 25-deacetylrifampin \[[@B15-antibiotics-09-00307]\]. The *AADAC* rs1803155 and rs61733693 variants which are missense mutations did not affect any changes in the plasma RF concentrations ([Table 6](#antibiotics-09-00307-t006){ref-type="table"}) \[[@B55-antibiotics-09-00307]\].

7. Vitamin D Pathway Gene Polymorphisms {#sec7-antibiotics-09-00307}
=======================================

The Caudal-type homeobox protein 2 (*Cdx2*) gene variant found in the regulatory region, *FokI* variant in exon 2 and *BsmI*, *TaqI* and *ApaI* variants in the 3′end of the *VDR* gene were found to be associated with TB \[[@B76-antibiotics-09-00307]\]. *BsmI* (rs1544410), *FokI* (rs10735810), *TaqI* (rs731236) and *ApaI* (rs7975232) represent the most commonly occurring SNPs of *VDR* gene \[[@B77-antibiotics-09-00307]\]. At the fourth week of ATT, univariate regression analysis revealed that *FokI* TC/CC genotype had a negative predictor role on the plasma RF C~trough~ (*p* = 0.694, β = −0.085, 95% CI \[-1314.809-891.285\]), possibly due to stronger transcription of the RF influx protein \[[@B38-antibiotics-09-00307]\]. The *FokI* variant codes for a shorter 424 amino acid VDR protein isoform which shows a comparatively higher transcriptional activity by displaying enhanced interaction with transcription factor IIB \[[@B78-antibiotics-09-00307]\]. Recently, Shaik et al. reported the frequencies of *FokI* TT, TC and CC genotypes to be 30.2%, 34.4% and 27.7%, respectively, in the Saudi Arabian population \[[@B79-antibiotics-09-00307]\]. Reports from the Brazilian population revealed the frequencies of *FokI* TT, TC and CC genotypes to be 44.6%, 41.4% and 14%, respectively \[[@B80-antibiotics-09-00307]\]. Calcagno et al. reported that the *VDR* regulatory region *Cdx2* variant was not associated with any significant changes in the plasma RF concentration \[[@B52-antibiotics-09-00307]\].

CYP27B1 and CYP24A1are two enzymes that are involved in the biotransformation of Vitamin D and play critical roles in governing the 1α,25-dihydroxyvitamin D~3~ (1,25-(OH)~2~D~3~) concentration. *CYP27B1* gene encodes for the 1α-hydroxylase enzyme that is involved in the activation of 25-hydroxyvitamin D~3~ (25-OH-D~3~) to 1,25-(OH)~2~D~3~ \[[@B81-antibiotics-09-00307]\]. *CYP24A1* is involved in catalyzing the C-23 and C-24 hydroxylation pathways of 25-OH-D~3~ and 1,25-(OH)~2~D~3~ \[[@B82-antibiotics-09-00307]\]. Hence, genetic variants of these genes may alter the Vitamin D levels and may thereby render TB susceptibility as well as alter RF concentrations in plasma. Allegra et al. reported that the *CYP24A1* rs927650 and *CYP27B1* rs4646536 variants increased plasma RF concentrations which may probably be explained by the increased activation of Vitamin D, resulting in reduced RF elimination ([Table 7](#antibiotics-09-00307-t007){ref-type="table"}) \[[@B38-antibiotics-09-00307]\]. Multivariate linear regression analysis revealed that *CYP27B1* rs4646536 variant (+ 2838C\>T; CC/CT genotype) located at intron 6 was a positive factor for RF C~max~ concentration ((*p* = 0.024, β = 0.416, 95% CI \[469.172--5857.279\]) at second week of ATT. Univariate linear regression analysis revealed that for the *CYP24A1* rs927650 (22776C\>T) variant located at intron 11, the homologous mutant profile (TT) is a positive predictor factor of RF C~trough~ ((*p* = 0.924, β = −0.021, 95% CI \[-1148.256-1055.303\]) at fourth week of ATT \[[@B38-antibiotics-09-00307]\]. The distribution of *CYP27B1* rs4646536 TT, TC and CC genotypes were reported to be 45.7%, 40.4% and 13.9%, respectively, in healthy controls of Germany which were in near similar lines with a previously conducted study among 7435 healthy controls of UK \[[@B83-antibiotics-09-00307],[@B84-antibiotics-09-00307]\]. The clear functional status of *CYP27B1* rs4646536 is unknown. Intronic variants could influence gene expression by affecting the binding of transcription factors and mRNA splicing \[[@B85-antibiotics-09-00307],[@B86-antibiotics-09-00307]\]. Hence, an allele variation of rs4646536 from C to T can cause abnormal expression of *CYP27B1*, resulting in the alteration of Vitamin D levels. *CYP27B1* rs4646536 was associated with Vitamin D levels and Vitamin-D-related diseases \[[@B84-antibiotics-09-00307]\]. The frequencies of *CYP24A1* rs927650 TT, CT and CC genotypes were reported to be 26.1%, 49.7% and 24.2%, respectively, in the healthy controls of Germany and 21.3%, 50.8% and 27.9%, respectively, among type 1 diabetes German patients \[[@B83-antibiotics-09-00307],[@B87-antibiotics-09-00307]\]. 1α,25(OH)~2~D~3~ exhibit genomic actions that are mediated through the ligand-binding to the VDR, which forms a heterodimer with retinoid x receptor alpha (RXRα) and subsequently binds to Vitamin D response elements (VDRE) to either enhance or repress transcription of various genes \[[@B88-antibiotics-09-00307]\]. The *CYP24A1* gene has a significant role in 1,25(OH)~2~D~3~ signaling as the promoter region of the *CYP24A1* gene contains VDRE \[[@B89-antibiotics-09-00307]\]. Polymorphisms in a VDRE of the *CYP24A1* gene could reduce the receptor protein binding, transactivation and expression of the *CYP24A1* gene in vivo \[[@B90-antibiotics-09-00307]\]. A suggestive relationship between the *CYP24A1* SNP rs927650 and concentrations of 25(OH)D was reported by Hibler et al. \[[@B91-antibiotics-09-00307]\]. Further research investigating the influence of *CYP27B1* and *CYP24A1* variants on Vitamin D levels and consequently on RF exposures are required to establish conclusive evidence.

8. Conclusions {#sec8-antibiotics-09-00307}
==============

Pharmacokinetic heterogeneity in RF levels represents an austere and ubiquitous problem in TB patient care. This can lead to therapeutic inefficacy, resistance, adverse drug events and increased healthcare expenditures. Genetic variants of *SLCO1B1*, *ABCB1* and *VDR* have attracted scientific attention for their influence on the pharmacokinetics of a wide range of drugs. While there is a vast number of studies that have explored the influence of SNPs with Isoniazid levels in plasma, only a limited number of studies have explored the influence of genetic variants on the RF pharmacokinetics. Evidence available to date reported a lack of any association of *ABCB1*, *PXR*, *CAR*, *CES1* and *AADAC* genetic variants with the RF concentrations in plasma. Some literature has shown an association of certain genetic variants of *SLCO1B1*, *CES2* and Vitamin D pathway genes with significant variations of RF concentration in plasma. A comprehensive exploration of the role of genetic variants of these genes can be initiated to provide a consensus agreement on their influence on RF pharmacokinetics in different populations.

Genotyping offers to be a potential tool of precision medicine for predicting individual drug-metabolizing and drug transport capabilities before initiation of RF treatment. Further studies assessing RF exposure and correlating it with the genetic polymorphisms are required in different ethnic populations. Besides, such research should be based on a representative and appropriate sample size to validate and implement a cost-effective genotyping-based RF dosage optimization in clinical settings and national policy levels.
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###### 

Influence of *SLCO1B1* genetic variants on plasma RF levels.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sl No.       Author, Year                                            Population                                                                SNP ID       Criteria of Sample Collection                   Time of Sample Collection                                                                 RF Concentration in Plasma
  ------------ ------------------------------------------------------- ------------------------------------------------------------------------- ------------ ----------------------------------------------- ----------------------------------------------------------------------------------------- ----------------------------
  1            Mukonzo et al., 2020 \[[@B48-antibiotics-09-00307]\]    50 TB patients from Uganda                                                rs4149056    After 21 days of ATT initiation                 Predose, 1, 2, 4, 6 and 12 h postdose                                                     No change

  rs2306283    No change                                                                                                                                                                                                                                                                                

  rs4149032    No change                                                                                                                                                                                                                                                                                

  2            Naidoo et al., 2019 \[[@B51-antibiotics-09-00307]\]     172 recurrent TB patients in South Africa                                 rs2306283    1 and/or 2 months and at 6 months during ATT    Predose, 2.5, 6 and 24 h postdose                                                         No change

  rs4149032    No change                                                                                                                                                                                                                                                                                

  rs4149056    No change                                                                                                                                                                                                                                                                                

  rs4149015    No change                                                                                                                                                                                                                                                                                

  3            Calcagno et al., 2019 \[[@B52-antibiotics-09-00307]\]   221 PTB with HIV patients in Uganda                                       rs4149032    At 2nd, 4th and 8th week of ATT                 1, 2 and 4 h postdose                                                                     No change

  4            Dompreh et al., 2018 \[[@B43-antibiotics-09-00307]\]    113 pediatric TB patients in Ghana                                        rs2306283    After 4 weeks of ATT                            Predose, 1, 2, 4 and 8 h postdose                                                         Decreased

  rs11045819   No change                                                                                                                                                                                                                                                                                

  rs4149056    No change                                                                                                                                                                                                                                                                                

  rs4149032    No change                                                                                                                                                                                                                                                                                

  5            Allegra et al., 2017 \[[@B38-antibiotics-09-00307]\]    24 TB patients in Italy                                                   rs4149056    At 2nd week and 4th week of ATT                 Plasma C~max~ (end of 3 infusions for IV route and 2 h postdose for oral) and C~trough~   Increased

  6            Sloan et al., 2017 \[[@B55-antibiotics-09-00307]\]      174 adult PTB patients in Malawi                                          rs11045819   Day 14 or 21 of ATT                             Predose, 2 and 6 h postdose                                                               No change

  rs4149032    No change                                                                                                                                                                                                                                                                                

  7            Ramesh et al., 2016 \[[@B53-antibiotics-09-00307]\]     256 South Indian adult PTB/EPTB patients                                  rs11045819   After a minimum of 2 weeks of ATT               2 h postdose                                                                              No change

  rs4149032    No change                                                                                                                                                                                                                                                                                

  rs4149033    No change                                                                                                                                                                                                                                                                                

  8            Jeremiah et al., 2014 \[[@B54-antibiotics-09-00307]\]   PTB patients in Tanzania                                                  rs4149032    1st occasion: 7 ± 2 days after ATT\             2, 4 and 6 h postdose                                                                     No change
                                                                                                                                                              2nd occasion: Around 56 days after ATT                                                                                                    

  9            Gengiah et al., 2014 \[[@B47-antibiotics-09-00307]\]    57 TB with HIV patients in South Africa                                   rs4149032    At 4th, 8th and 12th week of TB treatment       2.5 h postdose                                                                            Decreased

  10           Chigutsa et al., 2011 \[[@B46-antibiotics-09-00307]\]   60 PTB patients in South Africa                                           rs4149032    At least 1 month after the start of ATT         4 to 8 samples per patient, randomly collected over a 7 h period                          Decreased

  rs4149056    No change                                                                                                                                                                                                                                                                                

  rs11045819   No change                                                                                                                                                                                                                                                                                

  11           Weiner et al., 2010 \[[@B49-antibiotics-09-00307]\]     72 TB Patients (37 from Africa and 35 from the United States and Spain)   rs4149015    Between the 9th and 40th doses in TB patients   Just before dose and 1, 2, 6, 8 to 10, 11 to 13 and 23 to 25 h after dose                 No change

  rs2306283    No change                                                                                                                                                                                                                                                                                

  rs11045819   Decreased                                                                                                                                                                                                                                                                                

  rs4149056    No change                                                                                                                                                                                                                                                                                

  rs59502379   No change                                                                                                                                                                                                                                                                                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

antibiotics-09-00307-t002_Table 2

###### 

Influence of *ABCB1* genetic variants on plasma RF levels.

  Sl No.      Author, Year                                            Population                                  SNP ID       Criteria of Sample Collection                  Time of Sample Collection                                                                 RF Concentration in Plasma
  ----------- ------------------------------------------------------- ------------------------------------------- ------------ ---------------------------------------------- ----------------------------------------------------------------------------------------- ----------------------------
  1           Naidoo et al., 2019 \[[@B51-antibiotics-09-00307]\]     172 recurrent TB patients in South Africa   rs10276036   1 and/or 2 months and at 6 months during ATT   Predose, 2.5, 6 and 24 h postdose                                                         No change
  rs1128503   No change                                                                                                                                                                                                                                                 
  rs2032582   No change                                                                                                                                                                                                                                                 
  rs1045642   No change                                                                                                                                                                                                                                                 
  rs2235033   No change                                                                                                                                                                                                                                                 
  rs2235013   No change                                                                                                                                                                                                                                                 
  2           Calcagno et al., 2019 \[[@B52-antibiotics-09-00307]\]   221 PTB with HIV patients in Uganda         rs1045642    At 2nd, 4th and 8th week of ATT                1, 2 and 4 h postdose                                                                     No change
  3           Allegra et al., 2017 \[[@B38-antibiotics-09-00307]\]    24 TB patients in Italy                     rs1045642    At 2nd week and 4th week of ATT                Plasma C~max~ (end of 3 infusions for IV route and 2 h postdose for oral) and C~trough~   No change
  4           Chigutsa et al., 2011 \[[@B46-antibiotics-09-00307]\]   60 PTB patients in South Africa             rs1045642    At least 1 month after the start of ATT        4 to 8 samples per patient, randomly collected over a 7 h period                          No change
  rs2032582                                                                                                                                                                                                                                                             
  rs1128503                                                                                                                                                                                                                                                             
  rs3842                                                                                                                                                                                                                                                                

antibiotics-09-00307-t003_Table 3

###### 

Influence of *PXR* genetic variants on plasma RF levels.

  Sl No.      Author, Year                                            Population                                  SNP ID      Criteria of Sample Collection                  Time of Sample Collection                                                                 RF Concentration in Plasma
  ----------- ------------------------------------------------------- ------------------------------------------- ----------- ---------------------------------------------- ----------------------------------------------------------------------------------------- ----------------------------
  1           Naidoo et al., 2019 \[[@B51-antibiotics-09-00307]\]     172 recurrent TB patients in South Africa   rs2472677   1 and/or 2 months and at 6 months during ATT   Predose, 2.5, 6 and 24 h postdose                                                         No change
  rs1523130   No change                                                                                                                                                                                                                                                
  2           Calcagno et al., 2019 \[[@B52-antibiotics-09-00307]\]   221 PTB with HIV patients in Uganda         rs2472677   At 2nd, 4th and 8th week of ATT                1, 2 and 4 h postdose                                                                     No change
  3           Allegra et al., 2017 \[[@B38-antibiotics-09-00307]\]    24 TB patients in Italy                     rs2472677   At 2nd week and 4th week of ATT                Plasma C~max~ (end of 3 infusions for IV route and 2 h postdose for oral) and C~trough~   No change
  4           Chigutsa et al., 2011 \[[@B46-antibiotics-09-00307]\]   60 PTB patients in South Africa             rs2472677   At least 1 month after the start of ATT        4 to 8 samples per patient, randomly collected over a 7 h period                          No change
  rs1523130   No change                                                                                                                                                                                                                                                

antibiotics-09-00307-t004_Table 4

###### 

Influence of *CAR* genetic variants on plasma RF levels.

  Sl No.   Author, Year                                            Population                        SNP ID      Criteria of Sample Collection             Time of Sample Collection                                          RF Concentration in Plasma
  -------- ------------------------------------------------------- --------------------------------- ----------- ----------------------------------------- ------------------------------------------------------------------ ----------------------------
  1        Chigutsa et al., 2011 \[[@B46-antibiotics-09-00307]\]   60 PTB patients in South Africa   rs2307424   At least 1 month after the start of ATT   4 to 8 samples per patient, randomly collected over a 7 h period   No change

antibiotics-09-00307-t005_Table 5

###### 

Influence of *CES1* and *CES2* genetic variants on plasma RF levels.

  CES1                                                                                                                                                                                         
  ----------------------- ------------------------------------------------------ ------------------------------------ ------------- ---------------------- ----------------------------------- -----------
  1                       Sloan et al., 2017 \[[@B55-antibiotics-09-00307]\]     174 Adult PTB patients in Malawi     rs12149368    Day 14 or 21 of ATT    Predose, 2 and 6 h postdose         No change
  **CES2**                                                                                                                                                                                     
  1                       Dompreh et al., 2018 \[[@B43-antibiotics-09-00307]\]   113 Pediatric TB patients in Ghana   rs3759994     After 4 weeks of ATT   Predose, 1, 2, 4 and 8 h postdose   No change
  2                       Song et al., 2013 \[[@B74-antibiotics-09-00307]\]      35 TB patients in South Korea        c.-2548C\>T   \-                     2 h postdose                        No change
  c.-2263A\>G             Increased                                                                                                                                                            
  c.269-965A\>G           No change                                                                                                                                                            
  c.474-152T\>C           No change                                                                                                                                                            
  c.615+120G\>A           No change                                                                                                                                                            
  c.1612+136G\>A          No change                                                                                                                                                            
  c.1613-87G\>A           No change                                                                                                                                                            
  c.1872\*69A\>G          No change                                                                                                                                                            
  c.1872\*302_304delGAA   No change                                                                                                                                                            
  c.1872\*445C\>T         No change                                                                                                                                                            

antibiotics-09-00307-t006_Table 6

###### 

Influence of *AADAC* genetic variants on plasma RF levels.

  Sl No.       Author, Year                                         Population                         SNPs Investigated   Criteria of Sample Collection   Time of Sample Collection     RF Concentration in Plasma
  ------------ ---------------------------------------------------- ---------------------------------- ------------------- ------------------------------- ----------------------------- ----------------------------
  1            Sloan et al., 2017 \[[@B55-antibiotics-09-00307]\]   174 Adult PTB patients in Malawi   rs1803155           Day 14 or 21 of ATT             Predose, 2 and 6 h postdose   No change
  rs61733693                                                                                                                                                                             

antibiotics-09-00307-t007_Table 7

###### 

Influence of *VDR*, *CYP24A1* and *CYP27B1* genetic variants on plasma RF levels.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sl No.                Author, Year                                            Population                            Gene    SNP ID                Pharmacokinetic Sampling          Sample Timing                                                                             RF Concentration in Plasma
  --------------------- ------------------------------------------------------- ------------------------------------- ------- --------------------- --------------------------------- ----------------------------------------------------------------------------------------- ----------------------------
  1                     Calcagno et al., 2019 \[[@B52-antibiotics-09-00307]\]   221 PTB with HIV patients in Uganda   *VDR*   rs11568820 (*Cdx2*)   At 2nd, 4th and 8th week of ATT   1, 2 and 4 h postdose                                                                     No change

  2                     Allegra et al., 2017 \[[@B38-antibiotics-09-00307]\]    24 TB patients in Italy               *VDR*   rs731236 (*TaqI*)     At 2nd week and 4th week of ATT   Plasma C~max~ (end of 3 infusions for IV route and 2 h postdose for oral) and C~trough~   No change

  rs10735810 (*FokI*)   Decreased                                                                                                                                                                                                                                               

  rs1544410 (*BsmI*)    No change                                                                                                                                                                                                                                               

  rs11568820 (*Cdx2*)   No change                                                                                                                                                                                                                                               

  rs7975232\            No change                                                                                                                                                                                                                                               
  (*ApaI*)                                                                                                                                                                                                                                                                      

  *CYP24A1*             rs927650                                                Increased                                                                                                                                                                                       

  rs2248359             No change                                                                                                                                                                                                                                               

  rs2585428             No change                                                                                                                                                                                                                                               

  *CYP27B11*            rs4646536                                               Increased                                                                                                                                                                                       

  rs10877012            No change                                                                                                                                                                                                                                               
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
